Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents
- 22 April 2020
- journal article
- research article
- Published by Elsevier BV in Medical Hypotheses
- Vol. 140, 109777
- https://doi.org/10.1016/j.mehy.2020.109777
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Targeting natural killer cells in solid tumorsCellular & Molecular Immunology, 2019
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK CellsCell, 2018
- MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profileCytokine, 2018
- Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus FusionJournal of Virology, 2016
- Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunityJCI Insight, 2011
- SARS: Systematic Review of Treatment EffectsPLoS Medicine, 2006
- Plasma inflammatory cytokines and chemokines in severe acute respiratory syndromeClinical and Experimental Immunology, 2004
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004
- Effects of chloroquine on viral infections: an old drug against today's diseasesThe Lancet Infectious Diseases, 2003
- Lung pathology of fatal severe acute respiratory syndromeThe Lancet, 2003